Catherine Levitt - Astellas Pharma G Counsel
| YPH Stock | EUR 9.50 0.20 2.15% |
Insider
Catherine Levitt is G Counsel of Astellas Pharma
| Phone | 81 3 3244 3000 |
| Web | https://www.astellas.com |
Astellas Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0653 % which means that it generated a profit of $0.0653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0898 %, meaning that it generated $0.0898 on every $100 dollars invested by stockholders. Astellas Pharma's management efficiency ratios could be used to measure how well Astellas Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| David MD | Amgen Inc | 60 | |
| Jennifer Mauer | Merck Co | N/A | |
| Sarena Lin | Bayer AG NA | 52 | |
| Jonathan Graham | Amgen Inc | 62 | |
| Heiko Schipper | Bayer Aktiengesellschaft | 54 | |
| BerndPeter Bier | Bayer Aktiengesellschaft | 56 | |
| Wolfgang Nickl | Bayer AG NA | 54 | |
| Gabriel Harnier | Bayer Aktiengesellschaft | 52 | |
| Severin Schwan | Roche Holding Ltd | 56 | |
| Barbara Schadler | Roche Holding Ltd | 61 | |
| Dirk Brinckman | Johnson Johnson | N/A | |
| Rodrigo Santos | Bayer Aktiengesellschaft | 50 | |
| Michael Preuss | Bayer AG NA | N/A | |
| Werner Baumann | Bayer AG NA | 61 | |
| Esteban Santos | Amgen Inc | 55 | |
| Mike Zahigian | Amgen Inc | N/A | |
| Jessica Moore | Johnson Johnson | N/A | |
| Richard DeLuca | Merck Co | 60 | |
| James Swanson | Johnson Johnson | N/A | |
| Lisa LeCointeCephas | Merck Co | 41 | |
| Gabriel Harnier | Bayer AG NA | 52 | |
Management Performance
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 |
Astellas Pharma Leadership Team
Elected by the shareholders, the Astellas Pharma's board of directors comprises two types of representatives: Astellas Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Astellas. The board's role is to monitor Astellas Pharma's management team and ensure that shareholders' interests are well served. Astellas Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Astellas Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Minoru Kikuoka, CFO Officer | ||
| Naoki BSc, Chief VP | ||
| Kenji Yasukawa, CEO Pres | ||
| Stig Ogata, VP Communications | ||
| Katsuyoshi Sugita, Chief Officer | ||
| Chihiro Yokota, Devel Devel | ||
| Yoshitsugu Shitaka, Chief Officer | ||
| Nobue Yasuda, Gen Department | ||
| Catherine Levitt, G Counsel | ||
| Collette Taylor, VP HR |
Astellas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Astellas Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 24.85 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 50.33 % | |||
| Price To Earning | 29.54 X | |||
| Price To Book | 2.44 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Astellas Stock
Astellas Pharma financial ratios help investors to determine whether Astellas Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.